Michael Wang, MD

Articles

Michael Wang, MD, on Liso-Cel's Approval in Mantle Cell Lymphoma

June 6th 2024

The professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center discussed the advantages the newly approved CAR-T has for older, frailer patients.

Brexucabtagene Autoleucel in R/R Mantle Cell Lymphoma

Bijal D. Shah, MD;Caron Jacobson, MD;Michael Wang, MD;Ian Flinn, MD;Brian T. Hill, MD, PhD

January 29th 2022

Experts discussed the ZUMA-2 clinical trial of brexucabtagene autoleucel.

Liso-Cel's Efficacy in R/R Large B-Cell Lymphoma: Michael Wang, MD

Michael Wang, MD

January 16th 2022

The professor from University of Texas MD Anderson Cancer Center discussed the FDA approval of lisocabtagene maraleucel.

The Need for Academic and Community Collaboration With CAR T-Cell Therapy: Bijal Shah, MD; Michael Wang, MD

Bijal D. Shah, MD;Michael Wang, MD

January 3rd 2022

The hematologists from Moffitt Cancer Center and MD Anderson Cancer Center discussed the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.

Challenges in Managing High-Risk Mantle Cell Lymphoma: Bijal Shah, MD; Michael Wang, MD

Bijal D. Shah, MD;Michael Wang, MD

December 13th 2021

The hematologist from Moffitt Cancer Center and MD Anderson Cancer Center discussed CAR T-cell therapy and other treatment options for MCL.

Navigating CAR T-Cell Therapy Referrals: Bijal Shah, MD; Michael Wang, MD

Bijal Shah, MD, Moffit Cancer Center;Michael Wang, MD

December 12th 2021

The hematologists from Moffitt Cancer Center and University of Texas MD Anderson Cancer Center discussed navigating the referral process for CAR T-cell therapy in hematologic malignancies.

Managing CAR T-Associated Neurotoxicity and CRS: Bijal Shah, MD, MS; Michael Wang, MD

Bijal Shah, MD, Moffit Cancer Center;Michael Wang, MD

December 8th 2021

The hematologists from Moffitt Cancer Center and MD Anderson discussed managing CAR T-cell therapy-associated toxicities.

CAR T-Cell Therapy Associated Toxicities: Bijal Shah, MD, MS; Michael Wang, MD

Bijal Shah, MD, Moffit Cancer Center;Michael Wang, MD

December 7th 2021

The hematologists from Moffitt Cancer Center and The University of Texas MD Anderson Cancer Center discussed CAR T-associated toxicities.

Dr. Wang on Future Research With CAR T-Cell Therapy in MCL

Michael Wang, MD

August 5th 2020

Michael Wang, MD, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma.

$Dr. Wang on the Safety Profile of Brexucabtagene Autoleucel in Relapsed/Refractory MCL$

Dr. Wang on the Safety Profile of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

Michael Wang, MD

August 3rd 2020

Michael Wang, MD, discusses the safety profile of the CAR T-cell therapy brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma.

Dr. Wang on the Impact of KTE-X19 on Outcomes in Higher- Versus Lower-Risk MCL

Michael Wang, MD

June 10th 2020

Michael Wang, MD, discusses the safety and effectiveness of the autologous anti-CD19 CAR T-cell therapy KTE-X19 in patients with higher- versus lower-risk mantle cell lymphoma.

$Dr. Wang on the Utility of CAR T-Cell Therapy in Relapsed/Refractory MCL$

Dr. Wang on the Utility of CAR T-Cell Therapy in Relapsed/Refractory MCL

Michael Wang, MD

May 11th 2020

Michael Wang, MD, discusses the utility of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

$Dr. Wang on Unique Properties of KTE-X19 in Relapsed/Refractory MCL$

Dr. Wang on Unique Properties of KTE-X19 in Relapsed/Refractory MCL

Michael Wang, MD

May 5th 2020

Michael Wang, MD, discusses unique properties of the investigational CAR T-cell therapy KTE-X19 in relapsed/refractory mantle cell lymphoma.

Dr. Wang on the Safety Profile of KTE-X19 in MCL

Michael Wang, MD

March 3rd 2020

Michael Wang, MD, discusses the safety profile of the CAR T-cell therapy KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, according to results from the phase II ZUMA-2 trial.